©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 10, 2016; 7(1): 9-14
Published online Feb 10, 2016. doi: 10.5306/wjco.v7.i1.9
Published online Feb 10, 2016. doi: 10.5306/wjco.v7.i1.9
Current treatment options for patients with initially unresectable isolated colorectal liver metastases
Ozkan Kanat, Department of Medical Oncology, Uludag University Faculty of Medicine, 16059 Bursa, Turkey
Author contributions: Kanat O solely contributed to this manuscript.
Conflict-of-interest statement: The author has no financial disclosure or conflict of interest.
Correspondence to: Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Uludag University Faculty of Medicine, Gorukle, 16059 Bursa, Turkey. ozkanat@uludag.edu.tr
Telephone: +90-22-42951321
Received: June 9, 2015
Peer-review started: June 14, 2015
First decision: September 17, 2015
Revised: October 2, 2015
Accepted: December 1, 2015
Article in press: December 2, 2015
Published online: February 10, 2016
Processing time: 235 Days and 2.9 Hours
Peer-review started: June 14, 2015
First decision: September 17, 2015
Revised: October 2, 2015
Accepted: December 1, 2015
Article in press: December 2, 2015
Published online: February 10, 2016
Processing time: 235 Days and 2.9 Hours
Core Tip
Core tip: A subset of patients presenting with unresectable colorectal liver metastases (CLM) patients may become eligible for resection following systemic (chemotherapy ± biological therapy) and loco-regional treatments, including hepatic arterial infusion. After successful complete (R0) resection of liver lesions, these patients can achieve long-term survival. Therefore, all patients with CLM should be discussed in a multidisciplinary team meeting to identify appropriate treatment options.